BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    RHINO-LARYNGO VIDEOSCOPE

    MDR report key: 15726596 · Received November 4, 2022

    Report

    Report Number
    3002808148-2022-03788
    Event Type
    Malfunction
    Date Received
    November 4, 2022
    Date of Event
    October 2, 2022
    Report Date
    December 14, 2022
    Manufacturer
    SHIRAKAWA OLYMPUS CO., LTD.
    Product Code
    EOB
    UDI-DI
    04953170411526
    PMA / PMN Number
    K183416
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    JA
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    THE DEVICE REFERENCED IN THIS REPORT WAS NOT RETURNED TO OLYMPUS FOR EVALUATION. THE DEFINITIVE CAUSE OF THE USER'S EXPERIENCE CANNOT BE DETERMINED AT THIS TIME. THE INVESTIGATION IS ONGOING. THIS REPORT WILL BE UPDATED UPON COMPLETION OF THE INVESTIGATION OR UPON RECEIPT OF ADDITIONAL RELEVANT INFORMATION.

    Additional Manufacturer Narrative · 0

    THIS REPORT IS BEING SUPPLEMENTED TO PROVIDE ADDITIONAL INFORMATION BASED ON THE LEGAL MANUFACTURER'S FINAL INVESTIGATION. THE DEVICE HISTORY RECORD WAS UNABLE TO BE REVIEWED FOR THIS DEVICE SINCE THE SERIAL AND/OR LOT NUMBER WAS NOT PROVIDED. HOWEVER, OLYMPUS ONLY RELEASES PRODUCTS TO MARKET THAT MEET ALL MANUFACTURING SPECIFICATIONS AND FINAL PRODUCT RELEASE CRITERIA. BASED ON THE RESULTS OF THE INVESTIGATION, THE RELATIONSHIP BETWEEN THE DEVICE AND THE ADVERSE EVENT CANNOT BE CONFIRMED. THERE WAS NO COMPLAINT REPORTED ON THE SUBJECT DEVICE. THERE IS NO EVIDENCE OF AN OLYMPUS DEVICE MALFUNCTION. THEREFORE, THE ROOT CAUSE CANNOT BE DETERMINED. OLYMPUS WILL CONTINUE TO MONITOR FIELD PERFORMANCE FOR THIS DEVICE.

    Description of Event or Problem · 0

    IT IS REPORTED IN THE LITERATURE TITLED "DISINFECTION OF OTORHINOLARYNGOLOGICAL ENDOSCOPES WITH ELECTROLYZED ACID WATER: A CROSS-SECTIONAL AND MULTICENTER STUDY," OTORHINOLARYNGOLOGICAL ENDOSCOPES HAD POSITIVE MICROBIAL CULTURE AFTER CLEANING AND DISINFECTION. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS ENF-VH. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS ENF-V3. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS ENF-VQ. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS ENF-V2. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS ENF-VT2. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS ENF-VT3. GLUTARALDEHYDE, A GERMICIDE FOR REPROCESSING ENDOSCOPES THAT IS IMPORTANT FOR HYGIENE IN THE CLINIC, MIGHT BE HAZARDOUS TO HUMANS. ELECTROLYZED ACID WATER (EAW) HAS A BROAD ANTIMICROBIAL SPECTRUM AND SAFETY PROFILE AND MIGHT BE A GLUTARALDEHYDE ALTERNATIVE. WE SOUGHT TO ASSESS EAW DISINFECTION OF FLEXIBLE ENDOSCOPES IN CLINICAL OTORHINOLARYNGOLOGICAL SETTINGS AND IT¿S IN VITRO INACTIVATION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV2) AND BACTERIA COMMONLY ISOLATED IN OTORHINOLARYNGOLOGY. NINETY ENDOSCOPES WERE TESTED FOR BACTERIAL CONTAMINATION BEFORE AND AFTER ENDOSCOPE DISINFECTION WITH EAW. THE SPECIES AND STRAINS OF BACTERIA WERE STUDIED. THE IN VITRO INACTIVATION OF BACTERIA AND SARS-COV-2 BY EAW WAS INVESTIGATED TO DETERMINE THE EFFICACY OF ENDOSCOPE DISINFECTION. MORE THAN 20 COLONY-FORMING UNITS OF BACTERIA AT ONE OR MORE SAMPLING SITES WERE DETECTED IN 75/90 MICROBIOLOGICAL CULTURES OF SAMPLES FROM CLINICALLY USED ENDOSCOPES (83.3%). THE MOST COMMON GENUS DETECTED WAS STAPHYLOCOCCUS FOLLOWED BY CUTIBACTERIUM AND CORYNEBACTERIUM AT ALL SITES INCLUDING THE EARS, NOSES, AND THROATS. IN THE IN VITRO STUDY, MORE THAN 107 CFU/ML OF ALL BACTERIAL SPECIES EXAMINED WERE REDUCED TO BELOW THE DETECTION LIMIT (105 PFU) WAS DECREASED TO LESS THAN 5 PFU. EFFECTIVE INACTIVATION OF SARS-COV-2 WAS ALSO OBSERVED WITH A 19:1 RATIO OF EAW TO THE VIRUS. EAW EFFECTIVELY REPROCESSED FLEXIBLE ENDOSCOPES CONTRIBUTING TO INFECTION CONTROL IN MEDICAL INSTITUTIONS IN THE ERA OF THE CORONAVIRUS DISEASE 2019 PANDEMIC. AFTER THE MICROBIOLOGICAL CULTURE OF CLINICALLY USED ENDOSCOPES, MORE THAN 20 CFU OF BACTERIA AT ONE OR MORE SAMPLING SITES WAS DETECTED IN 75 OF 90 PATIENTS (83.3%). MORE SPECIFICALLY, MICROORGANISMS WERE DETECTED DIRECTLY AFTER CLINICAL USE WITHOUT DISINFECTION IN 13 OF 90 PATIENTS (14.4%), 74 OF 90 PATIENTS (82.2%), AND 9 OF 10 PATIENTS (90.0%) AT THE ENDOSCOPIC OPERATION SITE, ENDOSCOPIC INSERTION SITE, AND INSIDE THE ENDOSCOPIC SUCTION/FORCEPS CHANNEL, RESPECTIVELY. AFTER CLEANING AND DISINFECTION USING EAW, MICROORGANISMS WERE DETECTED IN ONLY ONE OF 75 ENDOSCOPES INSIDE THE ENDOSCOPIC SUCTION/FORCEPS CHANNEL WITH A VALUE OF 30 CFU, WHICH REPRESENTS A > ×105 REDUCTION IN A CLINICAL ENVIRONMENT. AFTER REPROCESSING WITH THE EAW, THE REMAINING 74 SAMPLES SHOWED NO FURTHER BACTERIAL CONTAMINATION. THIS STUDY DEMONSTRATED THAT THE EAW SYSTEM FOR REPROCESSING FLEXIBLE ENDOSCOPES APPEARS TO BE AN IDEAL DISINFECTION SYSTEM WITH A BROAD ANTI-MICROBIAL SPECTRUM WITH BOTH BACTERICIDAL AND VIRICIDAL EFFECTS AND SAFETY PROFILES. EAW DOES NOT HARM HUMAN TISSUES; THEREFORE, IT COULD BE AN ALTERNATIVE TO COMMONLY USED HIGH-LEVEL DISINFECTANTS INCLUDING GLUTARALDEHYDE, OPHTHALALDEHYDE, AND PERACETIC ACID. BECAUSE EAW DISINFECTANT PRODUCTION REQUIRES ONLY SALT, TAP WATER, AND ELECTRICITY, AND EAW LOSES ITS OXIDATIVE AND ACIDIC PROPERTIES WHEN EXPOSED TO THE ENVIRONMENT, THE USE OF EAW IN THE DISINFECTION OF OTORHINOLARYNGOLOGICAL ENDOSCOPES SHOULD CONTRIBUTE TO INFECTION CONTROL IN MEDICAL INSTITUTIONS FROM THE VIEWPOINTS OF SAFETY FOR MEDICAL STAFFS AND ENVIRONMENTAL FRIENDLINESS IN ORDER TO OVERCOME SUPPLY CRISIS DURING THE CORONAVIRUS DISEASE 2019 PANDEMIC, INDICATING SUSTAINABLE SYSTEMS AND ENABLING SAFE CONTINUITY.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    509931 RHINO-LARYNGO VIDEOSCOPE RHINO-LARYNGO VIDEOSCOPE EOB SHIRAKAWA OLYMPUS CO., LTD. ENF-VT3 04953170411526

    Patients

    Seq Age Sex Outcome Treatment
    1 Unknown